BioPulse

I really like $ALDX as a bounce play from $4. Extension and should get approval. 50% upside into PDUFA.

🧬 Weekly & YTD Biotech Moves ▸ Week ending 03/20/26 $XBI: -1.25% ($120.31) 🔴 $IBB: -2.33% ($161.65) 🔴 ▸ Year-to-date $XBI: -1.33% 🔴 $IBB: -4.22% 🔴 See image 👇

Saturday Night Live occasionally makes me laugh. Welcome to MAHAspital. Where emergencies are treated with beef tallow and raw eggs.

I know in my heart I need to be much bigger long $VKTX, and I already am pretty bigly long. This company below is trading at a P/E of 10! 10!!!! The biggest rocket ship of all time is taking off, and the next-gen version that for some reason dumbass $LLY didn’t make is trading for $4 billion. What the hell is happening in markets? $VKTX should probably be nearer $RVMD valuation. I know it sounds insane but what is oral tirzepatide worth!? And $NVO is trading like oral Wegovy is not going to do double digit billions next year (it definitely is).

$CLNN - Raised $28M, FDA meeting set for Q1 CNM-Au8 ALS biomarker data on deck. Competitors like $AMLX and $INSM will be watching closely.

$CLNN - A+ setup here. Don’t miss the 🚊 👀

New York City’s Credit Outlook Lowered to Negative by Moody’s

@BioValues Huge achievement well done!

$BTAI opportunity here.

$NVO ***FINALLY*** ended the $HIMS “personalized dosing” scam!!! $NVO had the leverage here, and this is a win/win for them ➡️ Stopping IP theft *and* increasing access to their legitimate channels in one swoop. Not the way I foresaw it playing out, but will give credit where it’s due to $NVO management: 100% the right business decision here.

IMO - latest AI capability should be good for flow into the BETTER catalyst trades YTG and beyond! Am I mad or yes Mabye?

Claude is now connected to the market.

$QURE RBC Capital upgrades uniQure to Outperform and raises price target to $35 from $11

I find it deliciously ironic that Vinay Prasad, the white knight of scientific integrity, is being defended by people publishing AI-generated slop.

$NVO Oral Wegovy TRx were +10% w/w, ending the week at ~73.5k vs. the prior week's ~66.7k; Oral Wegovy’s w/w growth rate has slowed down in recent weeks.

@Biotech2k1 @claudeai Love it!

I used @claudeai today to run a valuation on the Fintech companies I am looking at and it built me this beautiful spreadsheet. I thought I would share it.

$SRPT $QURE $REPL there it is! FDA'S VINAY PRASAD WILL DEPART IN APRIL, AFTER A YEAR LEADING THE DIVISION THAT APPROVES VACCINES AND BIOTECH DRUGS-WSJ

@Pharmdca Credit for shining a big torch on this name consistently on $DAWN !

$DAWN Gone. $VKTX Patience, fundamentals strong. Will be a huge winner as well.

$GUTS cash per share nearly 0.5+. Good risk reward now with multiple milestones for 2026 Q2 2026: U.S. Food and Drug Administration (FDA) feedback on potential for use of the De Novo pathway for Revita. Q2 2026: 1-year REVEAL-1 Cohort data. Q3 2026: 1-year REMAIN-1 Midpoint Cohort randomized data. Early Q4 2026: Topline 6-month randomized data from REMAIN-1 Pivotal Cohort. Late Q4 2026: Potential FDA marketing application submission in post-GLP-1 weight maintenance. The timing and form of submission may be informed by FDA feedback on the potential use of the De Novo pathway for Revita, which is currently expected in Q2 2026.

$DAWN most undervalued oncology stock period. Stock up on buyout rumors but regardless, long term stock could easily more double over time.

@VIPSheffTrades Great trade!